Vertex Acquires Crinetics for 102% Premium

Crinetics Pharmaceuticals (CRNX) received an offer from Vertex Pharmaceuticals (VRTX) to be acquired for $85/share, a 100% premium to recent levels. Vertex’s specialization in rare disease, including Type 1 Diabetes, makes CRNX a logical fit with its rare endocrine focus. Crinetics’ lead asset is a treatment for Congenital Adrenal Hyperplasia, a rare endocrine condition with only one approved therapy today. Crinetics’ therapy may offer a more convenient dosing paradigm with potentially better efficacy than standard of care.

• Vertex is paying $85/share cash, or ~$10.0B equity value / ~$8.8B net of estimated Crinetics cash acquired.

• Financing: Vertex expects to use cash on hand + debt, backed by $4.5B committed bridge financing.

• Strategic financial rationale: Vertex says Crinetics’ assets have >$5B combined annual peak revenue potential and should become non-GAAP operating-income accretive in 2029.

• Balance sheet capacity: Vertex ended Q1 2026 with $13.0B in cash, equivalents and marketable securities and guided to $12.95B–$13.1B 2026 revenue.

Metric	Detail
Offer price	$85/share cash
Equity value	~$10.0B
Net purchase value	~$8.8B net of estimated cash acquired
Financing	Cash + debt
Bridge financing	$4.5B committed
Crinetics Q1 2026 cash/investments	$1.3B
Vertex Q1 2026 cash/investments	$13.0B
Vertex 2026 revenue guide	$12.95B–$13.1B
Peak revenue opportunity	>$5B annually
Expected accretion	Non-GAAP operating income accretive in 2029

The transaction is best positioned as Vertex using balance sheet strength to buy durable rare-disease growth. Crinetics is not a purely speculative target: PALSONIFY generated $10.3M of Q1 2026 net product revenue, up from $5.4M in Q4 2025, while Crinetics also ended Q1 with $1.3B in cash, equivalents and investments.